Therapeutic Assays for the Identification and Characterization of Antiepileptic and Antiepileptogenic Drugs

Models of Seizures and Epilepsy

Volumn , Issue , 2006, Pages 539-549

  White, H Steve ^a   Smith Yockman, Misty ^a   Srivastava, Ajay ^a   Wilcox, Karen S ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882859574     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088554-1/50046-3     Document Type: Chapter

References (63)

1. Andre V., Ferrandon A., Marescaux C., Nehlig A. The lesional and epileptogenic consequences of lithium-pilocarpine-induced status epilepticus are affected by previous exposure to isolated seizures: effects of amygdala kindling and maximal electroshocks. Neuroscience 2000, 99(3):469-481.
2. Andre V., Ferrandon A., Marescaux C., Nehlig A. Vigabatrin protects against hippocampal damage but is not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy. Epilepsy Res 2001, 47(1-2):99-117.
3. Armand V., Rundfeldt C., Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. Epilepsia 2000, 41(1):28-33.
4. Barton M.E., Klein B.D., Wolf H.H., White H.S. Pharmacological characterization of the 6Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 2001, 47(3):217-227.
5. Barton M.E., Peters S.C., Shannon H.E. Comparison of the effect of glutamate receptor modulators in the 6 Hz and maximal electroshock seizure models. Epilepsy Res 2003, 56(1):17-26.
6. Brandt C., Volk H.A., Loscher W. Striking differences in individual anticonvulsant response to phenobarbital in rats with spontaneous seizures after status epilepticus. Epilepsia 2004, 45(12):1488-1497.
7. Brown W.C., Schiffman D.O., Swinyard E.A., Goodman L.S. Comparative assay of antiepileptic drugs by "psychomotor" seizure test and minimal electroshock threshold test. J Pharmacol Exp Ther 1953, 107:273-283.
8. Dalby N.O., Mody I. The process of epileptogenesis: a pathophysiological approach. Curr Opin Neurol 2001, 14(2):187-192.
9. Dube C.M., Chen K., Eghbal-Ahmadi M., Brunson K., Soltesz I., Baram T.Z. Prolonged febrile seizures in the immature rat model enhance hippocampal excitability long term. Ann Neurol 2000, 47(3):336-344.
10. Echlin F., Battista J. Epileptiform seizures from chronic isolated cortex. Arch Neurol 1963, 9:154-170.
11. Engstrom E.R., Hillered L., Flink R., et al. Extracellular amino acid levels measured with intracerebral microdialysis in the model of posttraumatic epilepsy induced by intracortical iron injection. Epilepsy Res 2001, 43:135-144.
12. Everett G.M., Richards R.K. Comparative anticonvulsive action of 3,5,5-trimethyloxazolidine-2,4-dione (Tridione), Dilantin and phenobarbital. J. Pharmacol Exp Ther 1944, 81:402-407.
13. Glien M., Brandt C., Potschka H., Loscher W. Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 2002, 43(4):350-357.
14. Golarai G., Greenwood A.C., Feeney D.M., Connor J.A. Physiological and structural evidence for hippocampal involvement in persistent seizure susceptibility after traumatic brain injury. J Neurosci 2001, 21(21):8523-8537.
15. Gower A.J., Hirsch E., Boehrer A., Noyer M., Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res 1995, 22(3):207-213.
16. Gower A.J., Noyer M., Verloes R., Gobert J., Wulfert E. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992, 222(2-3):193-203.
17. Grabenstatter H.L., Dudek F.E. The use of chronic models in antiepileptic drug discovery: The effect of RWJ-333369 on spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia 2004, 45(S7):197.
18. Grabenstatter H.L., Ferraro D.J., Williams P.A., Chapman P.L., Dudek F.E. Use of chronic epilepsy models in antiepileptic drug discovery: the effect of topiramate on spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia 2005, 46(1):8-14.
19. B receptor activation in absence seizures of lethargic (lh/lh) mice. Science 1992, 257:398-401.
20. Hosford D.A., Wang Y. Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia 1997, 38(4):408-414.
21. Jacobs M.P., Fischbach G.D., Davis M.R., et al. Future directions for epilepsy research. Neurology 2001, 57(9):1536-1542.
22. Jensen F.E., Blume H., Alvarado S., Firkusny I., Geary C. NBQX blocks acute and late epileptogenic effects of perinatal hypoxia. Epilepsia 1995, 36:966-972.
23. Kharatishvili I., McIntosh T.K., Pitkanen A. Association of hippocampal damage with the severity of epileptogenesis induced by fluid percussion injury in rat. Epilepsia 2004, 45(S7):45.
24. Klitgaard H., Matagne A., Gobert J., Wulfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998, 353(2-3):191-206.
25. Kupferberg H. Animal models used in the screening of antiepileptic drugs. Epilepsia 2001, 42(Suppl 4):7-12.
26. Lado F.A., Sankar R., Lowenstein D., Moshe S.L. Age-dependent consequences of seizures: relationship to seizure frequency, brain damage, and circuitry reorganization. Ment Retard Dev Disabil Res Rev 2000, 6(4):242-252.
27. Lado F.A., Sperber E.F., Moshe S.L. Anticonvulsant efficacy of gabapentin on kindling in the immature brain. Epilepsia 2001, 42(4):458-463.
28. Laurer H.L., McIntosh T.K. Experimental models of brain trauma. Curr Opin Neurol 1999, 12(6):715-721.
29. Leite J.P., Cavalheiro E.A. Effects of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats. Epilepsy Res 1995, 20(2):93-104.
30. Lennox W.G. The petit mal epilepsies. Their treatment with Tridione. JAMA 1945, 129:1069-1074.
31. Liptakova S., Velisek L., Veliskova J., Moshe S.L. Effect of ganaxolone on flurothyl seizures in developing rats. Epilepsia 2000, 41(7):788-793.
32. Loscher W. Animal models of intractable epilepsy. Prog Neurobiol 1997, 53(2):239-258.
33. Loscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and models with spontaneous recurrent seizures. Epilepsy Res 2002, 50(1-2):105-123.
34. Loscher W. Current status and future directions in the pharmacotherapy of epilepsy. Trends Pharmacol Sci 2002, 23(3):113-118.
35. Loscher W., Honack D. Responses to NMDA receptor antagonists altered by epileptogenesis. Trends Pharmacol Sci 1991, 12(2):52.
36. Loscher W., Honack D. Profile of ucb-L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 1993, 232(2-3):147-158.
37. Loscher W., Honack D., Rundfeldt C. Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 1998, 284(2):474-479.
38. Loscher W., Reissmuller E., Ebert U. Anticonvulsant efficacy of gabapentin and levetiracetam in phenytoin-resistant kindled rats. Epilepsy Res 2000, 40(1):63-77.
39. Lowenstein D.H., Thomas M.J., Smith D.H., McIntosh T.K. Selective vulnerability of dentate hilar neurons following traumatic brain injury: a potential mechanistic link between head trauma and disorders of the hippocampus. J Neurosci 1992, 12:4846-4853.
40. Marescaux C., Vergnes M. Genetic absence epilepsy in rats from Strasbourg (GAERS). Ital J Neurol Sci 1995, 16:113-118.
41. McNamara J.O. Analyses of the molecular basis of kindling development. Psychiatry Clin Neurosci 1995, 49(3):175-178.
42. Nissinen J., Halonen T., Koivisto E., Pitkanen A. A new model of chronic temporal lobe epilepsy induced by electrical stimulation of the amygdala in rat. Epilepsy Res 2000, 38(2-3):177-205.
43. Pitkanen A. New pharmacotherapy for epilepsy. Drugs 2004, 7(5):471-474.
44. Pitkanen A., Sutula T.P. Is epilepsy a progressive disorder? Prospects for new therapeutic approaches in temporal-lobe epilepsy. The Lancet Neurology 2002, 1:173-181.
45. Putnam T.J., Merritt H.H. Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science 1937, 85:525-526.
46. Rogawski M.A., Porter R.J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990, 42:223-286.
47. Sankar R., Shin D., Mazarati A.M., Liu H., Katsumori H., Lezama R., Wasterlain C.G. Epileptogenesis after status epilepticus reflects age- and model-dependent plasticity. Ann Neurol 2000, 48(4):580-589.
48. Santhakumar V., Ratzliff A.D., Jeng J., Toth Z., Soltesz I. Long-term hyperexcitability in the hippocampus after experimental head trauma. Ann Neurol 2001, 50:708-717.
49. Sharpless S., Halpern L. The electrical excitability of chronically isolated cortex studied by means of chronically implanted electrodes. Electroencephalogr Clin Neurophysiol 1962, 14:244-255.
50. Sloviter R.S. Permanently altered hippocampal structure, excitability, and inhibition after experimental status epilepticus in the rat: the "dormant basket cell" hypothesis and its possible relevance to temporal lobe epilepsy. Hippocampus 1991, 1(1):41-66.
51. Snead O.C. Pharmacological models of generalized absence seizures in rodents. J Neural Transm 1992, 35:7-19.
52. Stables J.P., Bertram E., Dudek F.E., Holmes G., Mathern G., Pitkanen A., White H.S. Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: summary of the NIH/NINDS/AES models II workshop. Epilepsia 2003, 44:1472-1478.
53. Suzdak P.D., Jansen J.A. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995, 36(6):612-626.
54. Temkin N.R. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001, 42(4):515-524.
55. Toth Z., Yan X.X., Haftoglou S., Ribak C.E., Baram T.Z. Seizure-induced neuronal injury: vulnerability to febrile seizures in an immature rat model. J Neurosci 1998, 18(11):4285-4294.
56. Velisek L., Veliskova J., Moshe S.L. Developmental seizure models. Ital J Neurol Sci 1995, 16(1-2):127-133.
57. Velisek L., Veliskova J., Ptachewich Y., Shinnar S., Moshe S.L. Effects of MK-801 and phenytoin on flurothyl-induced seizures during development. Epilepsia 1995, 36(2):179-185.
58. Walker M.C., White H.S., Sander J.W.A.S. Disease modification in partial epilepsy. Brain 2002, 125:1937-1950.
59. White H.S. Antiepileptic Drug Discovery. The Treatment of Epilepsy 2004, 89-95. Blackwell Science, Inc., Massachusettes. S.D. Shorvon, D.R. Fish, E. Perucca, W.E. Dodson (Eds.).
60. White H.S., Wolf H.H., Woodhead J.H., Kupferberg H.J. The National Institutes of Health Anticonvulsant Drug Development Program: Screening for Efficacy. Antiepileptic Drug Development. Advances in Neurology 1998, Vol 76:29-39. Lippincott-Raven Publishers, Philadelphia. J. French, I. Leppik, M.A. Dichter (Eds.).
61. White H.S., Woodhead J.H., Franklin M.R., Swinyard E.A., Wolf H.H. General principles: Experimental selection, quantification, and evaluation of antiepileptic drugs. Antiepileptic Drugs 1995, 99-110. Raven Press, New York. 4th Ed. R.H. Levy, R.H. Mattson, B.S. Meldrum (Eds.).
62. White H.S., Woodhead J.H., Wilcox K.S., Stables J.P., Kupferberg H.J., Wolf H.H. Discovery and preclinical development of antiepileptic drugs. Antiepileptic Drugs 2002, 36-48. Lippincott, Philadelphia. R.H. Levy, R.H. Mattson, B. Meldrum, E. Perucca (Eds.).
63. Willmore L.J., Sypert G.W., Munson J.V., Hurd R.W. Chronic focal epileptiform discharges induced by injection of iron into rat and cat cortex. Science 1978, 200:1501-1503.